



Docket No. JAB1701
Express Mail Label No. EV204058987US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lacrampre et al.

Serial No. : 10/520,768

Art Unit: 1624

Filed : January 10, 2005
V.Balasubramanian

Examiner:

For : 3-PHENYL ANALOGS OF TOXOFLAVIN AS KINASE
INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months

of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☒ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance

under §1.311 but before the payment of the Issue Fee.

Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1701/AGK. This form is submitted in triplicate.

Respectfully submitted,

Hesna J. Pfeiffer
/Hesna J. Pfeiffer/
Reg. No. 22,640
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1495
DATED: September 15, 2006



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
Express Mail Label No. EV204058987US

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	Application Number	10/520768
	Filing Date	01/10/2005
	First Named Inventor	Jean F. Lacrampe
	Group Art Unit	1624
	Examiner Name	V. Balasubramanian
	Attorney Docket Number	JAB 1701USWO

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		4568649		Immunex Corporation	02-04-1986	
		6174889	B1	Glaxo Wellcome Inc.	01-16-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		JP	09-255681	A	Taisho Pharmaceutical Co. Ltd. & English Abstract & Translation	09-30-1997		x
		JP	07-041479	B2	Taisho Pharmaceutical Co. Ltd. & English Abstract	02-10-1995		
		WO	02/20525	A2	Institute of Molecular And Cell Biology	03-14-2002		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; font-size: small;">(use as many sheets as necessary)</p> <p style="text-align: center; font-weight: bold;">Sheet 2 of 2</p>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px 5px;"><i>Application Number</i></td> <td style="padding: 2px 5px;">10/520768</td> </tr> <tr> <td style="padding: 2px 5px;"><i>Filing Date</i></td> <td style="padding: 2px 5px;">01/10/2005</td> </tr> <tr> <td style="padding: 2px 5px;"><i>First Named Inventor</i></td> <td style="padding: 2px 5px;">Jean F. Lacrampe</td> </tr> <tr> <td style="padding: 2px 5px;"><i>Group Art Unit</i></td> <td style="padding: 2px 5px;">1624</td> </tr> <tr> <td style="padding: 2px 5px;"><i>Examiner Name</i></td> <td style="padding: 2px 5px;">V. Balasubramanian</td> </tr> <tr> <td style="padding: 2px 5px;"><i>Attorney Docket Number</i></td> <td style="padding: 2px 5px;">JAB 1701USWO</td> </tr> </table>	<i>Application Number</i>	10/520768	<i>Filing Date</i>	01/10/2005	<i>First Named Inventor</i>	Jean F. Lacrampe	<i>Group Art Unit</i>	1624	<i>Examiner Name</i>	V. Balasubramanian	<i>Attorney Docket Number</i>	JAB 1701USWO
<i>Application Number</i>	10/520768												
<i>Filing Date</i>	01/10/2005												
<i>First Named Inventor</i>	Jean F. Lacrampe												
<i>Group Art Unit</i>	1624												
<i>Examiner Name</i>	V. Balasubramanian												
<i>Attorney Docket Number</i>	JAB 1701USWO												

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ABRAHAM et al., "Cellular Effects of Olomoucine, An Inhibitor of Cyclin-Dependent Kinases.", <i>Biol. Cell</i> , 1995, pages 105-120, Vol. 83.	
		DELIA, Thomas, "Fused Pyrimidines, Part Four, Miscellaneous Fused Pyrimidines: Chapter VI-Pyrimidotriazines.", <i>Heterocyclic Compounds</i> , John Wiley & Sons, Inc., Interscience Publications, pages 261-304.	
		GENNARO et al. <i>Remington's Pharmaceutical Sciences</i> , 19 th ed., Mack Publishing Company, 1990, see especially Part 8: Pharmaceutical preparations and their Manufacture.	
		GREENE et al., "Protective Groups in Organic Synthesis", 2 nd edition, Wiley Interscience, 1991.	
		KAUR et al., "Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275.", <i>Journal of the National Cancer Institute</i> , Nov. 18, 1992, pages 1736-1740, Vol. 84, No. 22.	
		MEIJER, Laurent, "Chemical Inhibitors of Cyclin-Dependent Kinases.", <i>Progress in Cell Cycle Research</i> , 1995, pages 351-363, Vol. 1.	
		NAGAMATSU et al., "Syntheses of 3-Substituted 1-Methyl-6-Phenylpyrimido[5,4-e]-1,2,4-triazine-5,7(1H,6H)-diones (6-Phenyl Analogs of Toxoflavin) and Their 4-Oxides, and Evaluation of Antimicrobial Activity of Toxoflavins and Their Analogs.", <i>Chem Pharm Bull.</i> , 1993, pages 362-368, Vol. 41, No. 2.	
		NAGAMATSU et al., "Facile And General Syntheses of 1-Alkyltoxoflavins and 8-Alkylfervenuin Derivatives of Biological Significance By The Regiospecific Alkylation of Reumycin (1-Demethyltoxoflavin, 8-Demethylfervenuin) Derivatives.", <i>Heterocycles</i> , 1997, pages 643-650, Vol. 45, No. 4.	
		NAGAMATSU et al., "General Syntheses of 1-Alkyltoxoflavin and 8-Alkylfervenuin Derivatives of Biological Significance By The Regioselective Alkylation of Reumycin Derivatives And The Rates of Transalkylation From 1-Alkyltoxoflavins Into Nucleophiles.", <i>J. Chem. Soc. Perkin Trans. 1</i> , 2001, pages 130-137.	
		"Protective Groups in Organic Chemistry", edited by J W F McOmie, 1973, Plenum Press.	
		SEDLACEK et al., "Flavopiridol (L86 8275; NSC 649890), A New Kinase Inhibitor For Tumor Therapy.", <i>International Journal of Oncology</i> , 1996, pages 1143-1168, Vol. 9.	
		SMIRNOVA et al., "Purines, Pyrimidines, And Condensed Systems Based on Them. 9."Concerning The Synthesis of 1-R-Pyrazolo[3,4-d]Pyrimidine-4,6-Diones.", 1992, pages 181-185, Plenum Publishing Corporation-Translated from <i>Khimiya Geterotsiklicheskikh Soedinenii</i> , Feb. 1992, pages 219-224, No. 2.	
		STREITWEISER, A., "Introduction to Organic Chemistry", Second Ed., Macmillan Publishing Inc., pages 1104-1105.	
		VESELY et al., "Inhibition of Cyclin-Dependent Kinases By Purine Analogues.", <i>Eur. J. Biochem.</i> , 1994, pages 771-786, Vol. 224.	
		YONEDA et al., "A Convenient Synthesis of Toxoflavins And Toxoflavin-N-Oxides.", <i>Tetrahedron Letters</i> , 1971, pages 851-854, Vol. 13, Pergamon Press, Great Britain.	
		YONEDA et al., "Transformation of Toxoflavins Into Fervenuin Via 1-Demethyltoxoflavins.", <i>Tetrahedron Letters</i> , 1973, pages 1577-1580, No. 17, Pergamon Press, Great Britain.	
		YONEDA et al., "Synthesis and Properties of 6-Benzyl Analogs of Toxoflavin.", <i>Journal of Heterocyclic Chemistry</i> , 1974, pages 83-85, Vol. 11, No. 1.	
		YONEDA et al., "A New Method For The Transformation of Toxoflavins to Fervenuins.", <i>Journal of Heterocyclic Chemistry</i> , 1974, pages 271-273, No. 11, No. 2.	
		YONEDA et al., "A New Synthetic Method of Toxoflavin Derivatives.", <i>Synthesis</i> , March 1975, pages 177-179, Vol. 3.	
		YONEDA et al., "A Convenient Synthesis of Toxoflavins, Toxoflavin 4-oxides and 1-Demethyltoxoflavins.", <i>Chem. Pharm. Bull.</i> , 1975, pages 2001-2009, Vol. 23, No. 9.	
		YONEDA et al., "New Syntheses of Fervenuin (1,3-Dimethyl-7-azaluzazine) and Analogs.", <i>Bulletin of The Chemical Society of Japan</i> , 1975, pages 2884-2887, Vol. 48, No. 10.	
		YONEDA et al., "A New Synthesis of Pyrimido[4,5-e]-as-triazine 4-Oxides by Nitrosative Cyclization of Aldehyde Uracil-6-ylhydrazones in the Presence of Diethyl Azodiformate.", <i>Journal of the Chemical Society</i> , 1976, pages 713-715, Vol. 7.	
		YONEDA et al., "6-Azapurines (Imidazo[4,5-e]-as-triazines).", <i>Journal of The Chemical Society, Chemical Communications</i> , 1976, pages 658-659, Vol. 16.	
		YONEDA et al., "Syntheses of Isoallozazines, Toxoflavins, and Fervenuins By Oxidative Cyclization of the Michael-type Adducts from Substituted 6-Aminouracils and Azo-Compounds.", <i>Journal of The Chemical Society, Perkin Transactions I</i> , 1976, pages 2398-2402, Vol. 22.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.